Skip to content

PD-1/PD-L1 inhibitor

DRUG9 trials

Sponsors

Tongji Hospital, Second Affiliated Hospital of Soochow University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jinling Hospital, China

Conditions

Advanced Solid TumorBiliary Tract CancerBiliary Tract Cancer (BTC)Carcinoma BreastCarcinoma, Non-Small-Cell LungLung CancerNon Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)

Phase 1

Phase 2

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
NCT05603013
Second Affiliated Hospital of Soochow UniversityCarcinoma Breast, Carcinoma, Non-Small-Cell Lung
Start: 2022-10-30End: 2024-10-17Target: 45Updated: 2022-11-02
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
NCT05790447
Second Affiliated Hospital of Soochow UniversityAdvanced Solid Tumor, Refractory Tumor
Start: 2023-04-01End: 2025-12-31Target: 60Updated: 2023-03-30
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
NCT06047860
Second Affiliated Hospital of Soochow UniversityAdvanced Solid Tumor, Refractory Tumor
Start: 2023-06-16End: 2024-12-31Target: 30Updated: 2023-09-21
Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib
Not yet recruitingNCT07230314
Jinling Hospital, ChinaUnresectable Hepatocellular Carcinoma
Start: 2025-11-30End: 2027-11-30Target: 34Updated: 2025-11-17
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
RecruitingNCT07282262
Peking Union Medical College HospitalBiliary Tract Cancer
Start: 2024-05-01End: 2026-10-01Target: 300Updated: 2025-12-15

Unknown Phase

Related Papers